EDITORIAL
Published on 10 Jan 2025
Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world
doi 10.3389/fphar.2024.1542453
- 227 views
- Frontiers in Pharmacology
- Pharmacoepidemiology
- Research Topics
- Biologic Drugs in Immune-Mediated Inflammatory Diseases: Validation, Drug-Utilization, Effectiveness, Regulation, Costs, and Safety in the Real World
Biologic Drugs in Immune-Mediated Inflammatory Diseases: Validation, Drug-Utilization, Effectiveness, Regulation, Costs, and Safety in the Real World
5,013
Total downloads
24k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 16 Oct 2024
Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study)
doi 10.3389/fphar.2024.1388043
- 648 views
SYSTEMATIC REVIEW
Published on 10 Oct 2024
A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis
doi 10.3389/fphar.2024.1440584
- 943 views
REVIEW
Published on 24 Jul 2024
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
doi 10.3389/fphar.2024.1424606
- 1,652 views
ORIGINAL RESEARCH
Published on 14 Jun 2024
Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
doi 10.3389/fphar.2024.1383212
- 1,172 views
- 2 citations
ORIGINAL RESEARCH
Published on 10 Jun 2024
Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland
doi 10.3389/fimmu.2024.1374829
- 1,090 views
ORIGINAL RESEARCH
Published on 14 Nov 2023
Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)
doi 10.3389/fphar.2023.1276340
- 3,691 views
- 4 citations
ORIGINAL RESEARCH
Published on 30 Oct 2023
Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study
doi 10.3389/fphar.2023.1266915
- 1,256 views
- 2 citations
ORIGINAL RESEARCH
Published on 25 Sep 2023
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
doi 10.3389/fphar.2023.1244486
- 1,385 views
CASE REPORT
Published on 23 May 2023
Successful treatment of a refractory intestinal Behcet’s disease with an oncology history by Vedolizumab: a case report and literature review
doi 10.3389/fimmu.2023.1205046
- 2,581 views
- 1 citation
Published in
Frontiers in Pharmacology
- Pharmacoepidemiology
- Gastrointestinal and Hepatic Pharmacology
Impact
- 24kTopic views
- 12kArticle views
- 5,013Article downloads